JP2020524660A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020524660A5 JP2020524660A5 JP2019566833A JP2019566833A JP2020524660A5 JP 2020524660 A5 JP2020524660 A5 JP 2020524660A5 JP 2019566833 A JP2019566833 A JP 2019566833A JP 2019566833 A JP2019566833 A JP 2019566833A JP 2020524660 A5 JP2020524660 A5 JP 2020524660A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- isoindole
- dihydro
- methylsulfonyl
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- -1 2 -cyclopropyl Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000001072 heteroaryl group Chemical group 0.000 claims description 5
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 5
- DUOAIECYOPBBFW-UHFFFAOYSA-N 2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)OC DUOAIECYOPBBFW-UHFFFAOYSA-N 0.000 claims description 4
- RLEMGVVMCGLKSZ-UHFFFAOYSA-N 2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-pyrrolidin-1-ylpropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(N1CCCC1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O RLEMGVVMCGLKSZ-UHFFFAOYSA-N 0.000 claims description 4
- HZIJEPFLDRAHBD-UHFFFAOYSA-N 2-acetyl-N-[4-(2-cyano-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]-5-(cyclopropylmethylsulfonyl)-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(C#N)(C(F)(F)F)C(F)(F)F)S(=O)(=O)CC1CC1 HZIJEPFLDRAHBD-UHFFFAOYSA-N 0.000 claims description 4
- ASKHYZJUQCANRW-UHFFFAOYSA-N 2-acetyl-N-[4-(2-cyano-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)C#N ASKHYZJUQCANRW-UHFFFAOYSA-N 0.000 claims description 4
- RGWUFVGHYGWNSD-UHFFFAOYSA-N CCS(=O)(=O)c1ccc2C(N(Cc2c1)C(C)=O)C(=O)Nc1ccc(cc1)C(C#N)(C(F)(F)F)C(F)(F)F Chemical compound CCS(=O)(=O)c1ccc2C(N(Cc2c1)C(C)=O)C(=O)Nc1ccc(cc1)C(C#N)(C(F)(F)F)C(F)(F)F RGWUFVGHYGWNSD-UHFFFAOYSA-N 0.000 claims description 4
- YXFUSIZOTILZCN-UHFFFAOYSA-N N-[4-(2-cyano-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]-2-(2-hydroxyacetyl)-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CS(=O)(=O)C1=CC=C2C(N(CC2=C1)C(=O)CO)C(=O)NC1=CC=C(C=C1)C(C#N)(C(F)(F)F)C(F)(F)F YXFUSIZOTILZCN-UHFFFAOYSA-N 0.000 claims description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims description 4
- 108091008778 RORγ2 Proteins 0.000 claims description 4
- 239000000808 adrenergic beta-agonist Substances 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- XQCPCVWYOKLTTD-UHFFFAOYSA-N methyl 1-[[4-(2-cyano-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]carbamoyl]-5-methylsulfonyl-1,3-dihydroisoindole-2-carboxylate Chemical compound COC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(C#N)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O XQCPCVWYOKLTTD-UHFFFAOYSA-N 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000003637 steroidlike Effects 0.000 claims description 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- VKRMELPCVIPJFE-UHFFFAOYSA-N 2-acetyl-5-methylsulfonyl-N-[4-[1,1,1,4-tetrafluoro-2-(trifluoromethyl)butan-2-yl]phenyl]-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(CCF)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O VKRMELPCVIPJFE-UHFFFAOYSA-N 0.000 claims description 2
- XNRWUOBKEMRGFX-UHFFFAOYSA-N 2-acetyl-5-methylsulfonyl-N-[4-[1,1,1-trifluoro-4-(3-fluoro-3-methylazetidin-1-yl)-4-oxo-2-(trifluoromethyl)butan-2-yl]phenyl]-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(CC(=O)N1CC(C)(F)C1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O XNRWUOBKEMRGFX-UHFFFAOYSA-N 0.000 claims description 2
- RXWXQHNBZLMZDF-UHFFFAOYSA-N 2-acetyl-5-methylsulfonyl-N-[4-[1,1,1-trifluoro-4-hydroxy-2-(trifluoromethyl)butan-2-yl]phenyl]-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(CCO)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O RXWXQHNBZLMZDF-UHFFFAOYSA-N 0.000 claims description 2
- WOTNJYJKOYIWQC-UHFFFAOYSA-N 2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-morpholin-4-ylpropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(N1CCOCC1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O WOTNJYJKOYIWQC-UHFFFAOYSA-N 0.000 claims description 2
- GAOIWDBXCXLDKQ-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(2-methylsulfonylethylamino)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCCS(=O)(=O)C GAOIWDBXCXLDKQ-UHFFFAOYSA-N 0.000 claims description 2
- IEDBORQSVIHAGT-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(2-methyltetrazol-5-yl)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CN1N=NC(=N1)C(C1=CC=C(NC(=O)C2N(CC3=CC(=CC=C23)S(C)(=O)=O)C(C)=O)C=C1)(C(F)(F)F)C(F)(F)F IEDBORQSVIHAGT-UHFFFAOYSA-N 0.000 claims description 2
- GPSRWFWMGTUVNE-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(methylamino)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CNC(C1=CC=C(NC(=O)C2N(CC3=CC(=CC=C23)S(C)(=O)=O)C(C)=O)C=C1)(C(F)(F)F)C(F)(F)F GPSRWFWMGTUVNE-UHFFFAOYSA-N 0.000 claims description 2
- URRHOUUUPBCOTM-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(oxan-4-ylamino)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(NC1CCOCC1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O URRHOUUUPBCOTM-UHFFFAOYSA-N 0.000 claims description 2
- VSNFVMFMNCMABQ-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(oxetan-3-ylamino)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(NC1COC1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O VSNFVMFMNCMABQ-UHFFFAOYSA-N 0.000 claims description 2
- YRXMARMJXCEXDK-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(propylamino)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CCCNC(C1=CC=C(NC(=O)C2N(CC3=CC(=CC=C23)S(C)(=O)=O)C(C)=O)C=C1)(C(F)(F)F)C(F)(F)F YRXMARMJXCEXDK-UHFFFAOYSA-N 0.000 claims description 2
- RFNLFLMYJOJFBU-UHFFFAOYSA-N 2-acetyl-N-[4-[1,1,1,3,3,3-hexafluoro-2-(triazol-1-yl)propan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)N1N=NC=C1 RFNLFLMYJOJFBU-UHFFFAOYSA-N 0.000 claims description 2
- QNDDYGXGFTZBDR-UHFFFAOYSA-N 2-acetyl-N-[4-[2-(cyanomethyl)-1,1,1,3,3,3-hexafluoropropan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(CC#N)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O QNDDYGXGFTZBDR-UHFFFAOYSA-N 0.000 claims description 2
- UAOFCKFQLBGBNL-UHFFFAOYSA-N 2-acetyl-N-[4-[4-(cyclopropylamino)-1,1,1-trifluoro-4-oxo-2-(trifluoromethyl)butan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(CC(=O)NC1CC1)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O UAOFCKFQLBGBNL-UHFFFAOYSA-N 0.000 claims description 2
- WHJCSIZYWZMUOT-UHFFFAOYSA-N C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C(=O)C1(CC1)OC Chemical compound C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C(=O)C1(CC1)OC WHJCSIZYWZMUOT-UHFFFAOYSA-N 0.000 claims description 2
- DQWBIFLELGTPSY-UHFFFAOYSA-N C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C(CN)=O Chemical compound C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C(CN)=O DQWBIFLELGTPSY-UHFFFAOYSA-N 0.000 claims description 2
- WXALMNFGEXJJPD-UHFFFAOYSA-N C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C=O Chemical compound C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1N(CC2=CC(=CC=C12)S(=O)(=O)C)C=O WXALMNFGEXJJPD-UHFFFAOYSA-N 0.000 claims description 2
- ZTUCBTPSVKQVNF-UHFFFAOYSA-N C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1NCC2=CC(=CC=C12)S(=O)(=O)C Chemical compound C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1NCC2=CC(=CC=C12)S(=O)(=O)C ZTUCBTPSVKQVNF-UHFFFAOYSA-N 0.000 claims description 2
- UDEVWCTWRJDXPF-UHFFFAOYSA-N C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1NCC2=CC(=CC=C12)S(=O)(=O)CC1CC1 Chemical compound C(#N)C(C(F)(F)F)(C(F)(F)F)C1=CC=C(C=C1)NC(=O)C1NCC2=CC(=CC=C12)S(=O)(=O)CC1CC1 UDEVWCTWRJDXPF-UHFFFAOYSA-N 0.000 claims description 2
- IWXMAJKSKUUECW-UHFFFAOYSA-N C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCC1(CC1)OC Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCC1(CC1)OC IWXMAJKSKUUECW-UHFFFAOYSA-N 0.000 claims description 2
- GQUCNCFIXLOCEA-UHFFFAOYSA-N C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCCCS(=O)(=O)C Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCCCS(=O)(=O)C GQUCNCFIXLOCEA-UHFFFAOYSA-N 0.000 claims description 2
- LVRAUXMTVIAQKV-UHFFFAOYSA-N C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCCOC(C)C Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)NCCOC(C)C LVRAUXMTVIAQKV-UHFFFAOYSA-N 0.000 claims description 2
- JORCSRDCGQIINM-UHFFFAOYSA-N C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(CC(=O)NC(C)(C)C)C(F)(F)F Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(CC(=O)NC(C)(C)C)C(F)(F)F JORCSRDCGQIINM-UHFFFAOYSA-N 0.000 claims description 2
- OCPRERHQVMDKDG-UHFFFAOYSA-N CS(=O)(=O)c1ccc2C(N(Cc2c1)C(=O)CCC(O)=O)C(=O)Nc1ccc(cc1)C(C#N)(C(F)(F)F)C(F)(F)F Chemical compound CS(=O)(=O)c1ccc2C(N(Cc2c1)C(=O)CCC(O)=O)C(=O)Nc1ccc(cc1)C(C#N)(C(F)(F)F)C(F)(F)F OCPRERHQVMDKDG-UHFFFAOYSA-N 0.000 claims description 2
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 claims description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 2
- CCNYRPPTTRLYBS-UHFFFAOYSA-N N-[4-(2-cyano-1,1,1,3,3,3-hexafluoropropan-2-yl)phenyl]-2-(2-methoxyacetyl)-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound COCC(=O)N1CC2=CC(=CC=C2C1C(=O)NC1=CC=C(C=C1)C(C#N)(C(F)(F)F)C(F)(F)F)S(C)(=O)=O CCNYRPPTTRLYBS-UHFFFAOYSA-N 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 239000001294 propane Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- JZYDSFJUWQIHGK-UHFFFAOYSA-N C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(CC(=O)NCCF)C(F)(F)F Chemical compound C(C)(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(CC(=O)NCCF)C(F)(F)F JZYDSFJUWQIHGK-UHFFFAOYSA-N 0.000 claims 1
- WUGQZFFCHPXWKQ-UHFFFAOYSA-N Propanolamine Chemical compound NCCCO WUGQZFFCHPXWKQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- SKYFVUSZPNOYJH-UHFFFAOYSA-N 2-acetyl-N-[4-[2-(dimethylamino)-1,1,1,3,3,3-hexafluoropropan-2-yl]phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CN(C)C(C1=CC=C(NC(=O)C2N(CC3=CC(=CC=C23)S(C)(=O)=O)C(C)=O)C=C1)(C(F)(F)F)C(F)(F)F SKYFVUSZPNOYJH-UHFFFAOYSA-N 0.000 description 1
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
- ZVFBLDFWLWLCPI-UHFFFAOYSA-N N-[4-[4-acetamido-1,1,1-trifluoro-2-(trifluoromethyl)butan-2-yl]phenyl]-2-acetyl-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound CC(=O)NCCC(C1=CC=C(NC(=O)C2N(CC3=CC(=CC=C23)S(C)(=O)=O)C(C)=O)C=C1)(C(F)(F)F)C(F)(F)F ZVFBLDFWLWLCPI-UHFFFAOYSA-N 0.000 description 1
- FDYONACYJSKWCA-UHFFFAOYSA-N NCCC(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)C#N Chemical compound NCCC(=O)N1C(C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)C#N FDYONACYJSKWCA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762519263P | 2017-06-14 | 2017-06-14 | |
| US62/519,263 | 2017-06-14 | ||
| PCT/EP2018/065712 WO2018229155A1 (en) | 2017-06-14 | 2018-06-13 | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020524660A JP2020524660A (ja) | 2020-08-20 |
| JP2020524660A5 true JP2020524660A5 (enExample) | 2021-07-26 |
Family
ID=62684777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019566833A Ceased JP2020524660A (ja) | 2017-06-14 | 2018-06-13 | Ｒｏｒ−ガンマモジュレーターとして有用な２，３−ジヒドロイソインドール−１−カルボキサミド |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11034654B2 (enExample) |
| EP (1) | EP3638661A1 (enExample) |
| JP (1) | JP2020524660A (enExample) |
| CN (1) | CN110730780A (enExample) |
| WO (1) | WO2018229155A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020035557A1 (en) * | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| WO2020035556A1 (en) * | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
| JP2023533123A (ja) * | 2020-05-15 | 2023-08-02 | シャンハイ ライテッド カンパニー リミテッド | ＲＯＲγ調節剤として使用可能なアニリン化合物 |
| CN113717090B (zh) * | 2021-08-31 | 2022-04-05 | 南京林业大学 | 一种含三氟甲基全碳季碳中心吲哚乙腈化合物及其制备方法和应用 |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
| US6066738A (en) | 1996-01-30 | 2000-05-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EA200000873A1 (ru) | 1998-02-25 | 2001-04-23 | Дженетикс Инститьют, Инк. | Ингибиторы фосфолипазы a |
| US6316503B1 (en) | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
| EP1212065A4 (en) | 1999-07-08 | 2004-02-11 | Tularik Inc | COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL |
| CN1244561C (zh) | 2000-05-11 | 2006-03-08 | 布里斯托尔-迈尔斯斯奎布公司 | 可用作生长激素促分泌素的四氢异喹啉类似物 |
| US6777446B2 (en) | 2000-09-05 | 2004-08-17 | Tularik, Inc. | FXR modulators |
| JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
| EP1353662B1 (en) | 2001-01-26 | 2007-04-18 | Chugai Seiyaku Kabushiki Kaisha | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| EP1511483A4 (en) | 2002-03-27 | 2009-03-18 | Smithkline Beecham Corp | PROCESSING METHODS USING LXR MODULATORS |
| AU2003227689A1 (en) | 2002-04-29 | 2003-11-17 | Novartis Ag | Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha) |
| EP1646394A2 (en) | 2003-07-22 | 2006-04-19 | Glaxo Group Limited | Methods of treatment with lxr agonists |
| WO2005013946A2 (en) | 2003-07-28 | 2005-02-17 | Glaxo Group Limited | Methods of treatment inflammatory bowel with lxr agonists |
| WO2005055998A1 (en) | 2003-12-04 | 2005-06-23 | Smithkline Beecham Corporation | Methods of treatment with lxr agonists |
| WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
| WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2007146712A2 (en) | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
| WO2008008020A1 (en) | 2006-07-12 | 2008-01-17 | Astrazeneca Ab | 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
| TW200812962A (en) | 2006-07-12 | 2008-03-16 | Astrazeneca Ab | New compounds I/418 |
| DK2076260T3 (da) | 2006-09-15 | 2011-06-27 | Celgene Corp | N-methylaminomethyl-isoindol-forbindelser og sammensætninger, der indeholder disse, samt fremgangsmåder til deres anvendelse |
| JP4834699B2 (ja) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | 医薬組成物 |
| JP4846769B2 (ja) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
| WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
| WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
| WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
| EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
| US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
| WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
| WO2013100027A1 (ja) | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | 複素環化合物 |
| US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| WO2013159095A1 (en) | 2012-04-20 | 2013-10-24 | Anderson Gaweco | Ror modulators and their uses |
| EP2844259A4 (en) | 2012-04-30 | 2015-11-11 | Anderson Gaweco | MMR MODULATORS AND USES THEREOF |
| EP2844260A4 (en) | 2012-04-30 | 2016-06-29 | Anderson Gaweco | ROR MODULATORS AND ITS USES |
| WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
| WO2014125426A1 (en) | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
| US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| US9868748B2 (en) | 2013-05-01 | 2018-01-16 | Vitae Pharmaceuticals, Inc. | Thiazolopyrrolidine inhibitors of ROR- γ |
| WO2015002230A1 (ja) | 2013-07-03 | 2015-01-08 | 武田薬品工業株式会社 | アミド化合物 |
| EP3018126A4 (en) | 2013-07-03 | 2016-12-07 | Takeda Pharmaceuticals Co | HETEROCYCLIC CONNECTION |
| WO2015017335A1 (en) | 2013-07-30 | 2015-02-05 | Boehringer Ingelheim International Gmbh | Azaindole compounds as modulators of rorc |
| WO2015035032A1 (en) | 2013-09-05 | 2015-03-12 | Boehringer Ingelheim International Gmbh | Bicylic compounds as modulators of rorgamma |
| HUE043258T2 (hu) | 2013-12-05 | 2019-08-28 | Lead Pharma Holding Bv | ROR gamma (RORy) modulátorok |
| WO2015083130A1 (en) | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
| WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
| UA121309C2 (uk) | 2014-02-03 | 2020-05-12 | Вітае Фармасьютікалс, Ллс | Дигідропіролопіридинові інгібітори ror-гамма |
| WO2015129853A1 (ja) | 2014-02-27 | 2015-09-03 | 東レ株式会社 | 環状アミン誘導体及びその医薬用途 |
| WO2015145371A1 (en) | 2014-03-27 | 2015-10-01 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
| AU2015247983B2 (en) | 2014-04-14 | 2019-05-16 | Boehringer Ingelheim International Gmbh | Compounds as modulators of ROR gamma |
| SG11201607518RA (en) | 2014-04-16 | 2016-10-28 | Glenmark Pharmaceuticals Sa | Aryl and heteroaryl ether compounds as ror gamma modulators |
| US9365520B2 (en) | 2014-07-01 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2016020288A1 (en) | 2014-08-04 | 2016-02-11 | Nuevolution A/S | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
| MA40759A (fr) | 2014-09-26 | 2017-08-01 | Pfizer | Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation |
| BR112017007460A2 (pt) | 2014-10-14 | 2017-12-19 | Vitae Pharmaceuticals Inc | inibidores de di-hidropirrolopiridina de ror-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| JP2017538676A (ja) | 2014-11-05 | 2017-12-28 | ザ ユニバーシティ オブ カンザス | ミトコンドリア透過性遷移孔（ｍｔＰＴＰ）の小分子阻害剤 |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| US20180110774A1 (en) | 2015-04-28 | 2018-04-26 | Stc. Unm | Compositions and methods for treatment of pulmonary hypertension |
| MX385357B (es) | 2015-05-15 | 2025-03-18 | Aurigene Discovery Tech Ltd | Compuestos de tetrahidroquinolinona sustituidos como moduladores de ror gamma |
| EP3101005A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101008A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101009A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101006A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3101007A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| WO2017010399A1 (ja) | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | ＲＯＲγｔ阻害作用を有する化合物およびそれらを含有する医薬組成物 |
| ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
| WO2017058831A1 (en) | 2015-10-01 | 2017-04-06 | Boehringer Ingelheim International Gmbh | Pteridine derivatives as modulators of ror gamma |
| TWI728017B (zh) | 2015-12-15 | 2021-05-21 | 瑞典商阿斯特捷利康公司 | 異吲哚化合物、包含其之醫藥組成物及其用途 |
-
2018
- 2018-06-13 CN CN201880038447.4A patent/CN110730780A/zh active Pending
- 2018-06-13 US US16/621,872 patent/US11034654B2/en not_active Expired - Fee Related
- 2018-06-13 JP JP2019566833A patent/JP2020524660A/ja not_active Ceased
- 2018-06-13 WO PCT/EP2018/065712 patent/WO2018229155A1/en not_active Ceased
- 2018-06-13 EP EP18732711.9A patent/EP3638661A1/en not_active Withdrawn
-
2021
- 2021-05-07 US US17/314,256 patent/US20210380533A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020524660A5 (enExample) | ||
| RU2361860C2 (ru) | Новые замещенные 3-сера-индолы | |
| JP2014502979A5 (enExample) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2008502700A5 (enExample) | ||
| JP2007519754A5 (enExample) | ||
| JP2011529037A5 (enExample) | ||
| JP2017523972A5 (enExample) | ||
| RU2009126624A (ru) | Производные 2-(пиперидин-4-ил)-4-фенокси-или фенилаинопиримидина в качестве ненуклеозидных ингибитров обратной транскриптазы | |
| JP2009503107A5 (enExample) | ||
| JP2021501179A5 (enExample) | ||
| JP2013507449A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| RU2013130879A (ru) | Производные оксазолилметилового эфира в качестве агонистов рецептора alx | |
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| JP2019537603A5 (enExample) | ||
| RU2011153772A (ru) | Фторированные аминотриазольные производные | |
| RU2007119427A (ru) | Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе | |
| JP2016020375A5 (enExample) | ||
| RU2014148316A (ru) | Производные 1-фенил-2-пиридинил-алкиловых спиртов в качестве ингибиторов фосфодиэстеразы | |
| JP2013544811A5 (enExample) | ||
| JP2010536821A5 (enExample) | ||
| RU2000131184A (ru) | Соединения, обладающие свойствами, способствующими выделению гормона роста | |
| JP2020502058A5 (enExample) | ||
| JP2017509694A5 (enExample) |